488 related articles for article (PubMed ID: 30651314)
1. α-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease.
Levine PM; Galesic A; Balana AT; Mahul-Mellier AL; Navarro MX; De Leon CA; Lashuel HA; Pratt MR
Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1511-1519. PubMed ID: 30651314
[TBL] [Abstract][Full Text] [Related]
2. O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson's disease.
Marotta NP; Lin YH; Lewis YE; Ambroso MR; Zaro BW; Roth MT; Arnold DB; Langen R; Pratt MR
Nat Chem; 2015 Nov; 7(11):913-20. PubMed ID: 26492012
[TBL] [Abstract][Full Text] [Related]
3. O-GlcNAc modification inhibits the calpain-mediated cleavage of α-synuclein.
Levine PM; De Leon CA; Galesic A; Balana A; Marotta NP; Lewis YE; Pratt MR
Bioorg Med Chem; 2017 Sep; 25(18):4977-4982. PubMed ID: 28487126
[TBL] [Abstract][Full Text] [Related]
4. O-GlcNAcylation of α-Synuclein at Serine 87 Reduces Aggregation without Affecting Membrane Binding.
Lewis YE; Galesic A; Levine PM; De Leon CA; Lamiri N; Brennan CK; Pratt MR
ACS Chem Biol; 2017 Apr; 12(4):1020-1027. PubMed ID: 28195695
[TBL] [Abstract][Full Text] [Related]
5. O-GlcNAcylation of truncated NAC segment alters peptide-dependent effects on α-synuclein aggregation.
Ryan P; Xu MM; Davey AK; Kassiou M; Mellick GD; Rudrawar S
Bioorg Chem; 2020 Jan; 94():103389. PubMed ID: 31753312
[TBL] [Abstract][Full Text] [Related]
6. O-GlcNAcylation inhibits the oligomerization of alpha-synuclein by declining intermolecular hydrogen bonds through a steric effect.
Wu K; Li D; Xiu P; Ji B; Diao J
Phys Biol; 2020 Dec; 18(1):016002. PubMed ID: 32906104
[TBL] [Abstract][Full Text] [Related]
7. O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.
Ryan P; Xu M; Davey AK; Danon JJ; Mellick GD; Kassiou M; Rudrawar S
ACS Chem Neurosci; 2019 May; 10(5):2209-2221. PubMed ID: 30985105
[TBL] [Abstract][Full Text] [Related]
8. O-GlcNAc forces an α-synuclein amyloid strain with notably diminished seeding and pathology.
Balana AT; Mahul-Mellier AL; Nguyen BA; Horvath M; Javed A; Hard ER; Jasiqi Y; Singh P; Afrin S; Pedretti R; Singh V; Lee VM; Luk KC; Saelices L; Lashuel HA; Pratt MR
Nat Chem Biol; 2024 May; 20(5):646-655. PubMed ID: 38347213
[TBL] [Abstract][Full Text] [Related]
9. O-GlcNAc regulation of autophagy and α-synuclein homeostasis; implications for Parkinson's disease.
Wani WY; Ouyang X; Benavides GA; Redmann M; Cofield SS; Shacka JJ; Chatham JC; Darley-Usmar V; Zhang J
Mol Brain; 2017 Jul; 10(1):32. PubMed ID: 28724388
[TBL] [Abstract][Full Text] [Related]
10. Investigating the Effects of O-GlcNAc Modifications in Parkinson's Disease Using Semisynthetic α-Synuclein.
Galesic A; Pratt MR
Methods Mol Biol; 2020; 2133():313-326. PubMed ID: 32144674
[TBL] [Abstract][Full Text] [Related]
11. Post-translational modification of α-synuclein in Parkinson's disease.
Barrett PJ; Timothy Greenamyre J
Brain Res; 2015 Dec; 1628(Pt B):247-253. PubMed ID: 26080075
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation and O-GlcNAcylation at the same α-synuclein site generate distinct fibril structures.
Hu J; Xia W; Zeng S; Lim YJ; Tao Y; Sun Y; Zhao L; Wang H; Le W; Li D; Zhang S; Liu C; Li YM
Nat Commun; 2024 Mar; 15(1):2677. PubMed ID: 38538591
[TBL] [Abstract][Full Text] [Related]
13. The Sulfur-Linked Analogue of O-GlcNAc (S-GlcNAc) Is an Enzymatically Stable and Reasonable Structural Surrogate for O-GlcNAc at the Peptide and Protein Levels.
De Leon CA; Levine PM; Craven TW; Pratt MR
Biochemistry; 2017 Jul; 56(27):3507-3517. PubMed ID: 28627871
[TBL] [Abstract][Full Text] [Related]
14. Enzymatic O-GlcNAcylation of α-synuclein reduces aggregation and increases SDS-resistant soluble oligomers.
Zhang J; Lei H; Chen Y; Ma YT; Jiang F; Tan J; Zhang Y; Li JD
Neurosci Lett; 2017 Aug; 655():90-94. PubMed ID: 28673834
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic roles for altered O-GlcNAcylation in neurodegenerative disorders.
Balana AT; Pratt MR
Biochem J; 2021 Jul; 478(14):2733-2758. PubMed ID: 34297044
[TBL] [Abstract][Full Text] [Related]
16. Initiation and propagation of α-synuclein aggregation in the nervous system.
Hijaz BA; Volpicelli-Daley LA
Mol Neurodegener; 2020 Mar; 15(1):19. PubMed ID: 32143659
[TBL] [Abstract][Full Text] [Related]
17. O-GlcNAc modification prevents peptide-dependent acceleration of α-synuclein aggregation.
Marotta NP; Cherwien CA; Abeywardana T; Pratt MR
Chembiochem; 2012 Dec; 13(18):2665-70. PubMed ID: 23143740
[TBL] [Abstract][Full Text] [Related]
18. CSPα reduces aggregates and rescues striatal dopamine release in α-synuclein transgenic mice.
Caló L; Hidari E; Wegrzynowicz M; Dalley JW; Schneider BL; Podgajna M; Anichtchik O; Carlson E; Klenerman D; Spillantini MG
Brain; 2021 Jul; 144(6):1661-1669. PubMed ID: 33760024
[TBL] [Abstract][Full Text] [Related]
19. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
[TBL] [Abstract][Full Text] [Related]
20. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
Sahay S; Ghosh D; Singh PK; Maji SK
Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
